12 results on '"Harewood, R"'
Number of results to display per page
Search Results
2. Population-Based Cancer Survival in Canada and the United States by Socioeconomic Status: Findings from the CONCORD-2 Study.
- Author
-
Weir HK, Bryant H, Turner D, Coleman MP, Mariotto AB, Spika D, Matz M, Harewood R, Tucker TC, and Allemani C
- Subjects
- Adult, Aged, Child, Female, Humans, Male, Canada epidemiology, Insurance, Health, Social Class, United States epidemiology, Infant, Newborn, Infant, Child, Preschool, Adolescent, Young Adult, Middle Aged, National Health Programs, Neoplasms epidemiology, Neoplasms therapy, Neoplasms diagnosis
- Abstract
Background: Population-based cancer survival provides insight into the effectiveness of health systems to care for all residents with cancer, including those in marginalized groups., Methods: Using CONCORD-2 data, we estimated 5-year net survival among patients diagnosed 2004-2009 with one of 10 common cancers, and children diagnosed with acute lymphoblastic leukemia (ALL), by socioeconomic status (SES) quintile, age (0-14, 15-64, ≥65 years), and country (Canada or United States)., Results: In the lowest SES quintile, survival was higher among younger Canadian adults diagnosed with liver (23% vs 15%) and cervical (78% vs 68%) cancers and with leukemia (62% vs 56%), including children diagnosed with ALL (92% vs 86%); and higher among older Americans diagnosed with colon (62% vs 56%), female breast (87% vs 80%), and prostate (97% vs 85%) cancers. In the highest SES quintile, survival was higher among younger Americans diagnosed with stomach cancer (33% vs 27%) and younger Canadians diagnosed with liver cancer (31% vs 23%); and higher among older Americans diagnosed with stomach (27% vs 22%) and prostate (99% vs 92%) cancers., Conclusions: Among younger Canadian cancer patients in the lowest SES group, greater access to health care may have resulted in higher cancer survival, while higher screening prevalence and access to health insurance (Medicare) among older Americans during the period of this study may have resulted in higher survival for some screen-detected cancers. Higher survival in the highest SES group for stomach and liver may relate to treatment differences. Survival differences by age and SES between Canada and the United States may help inform cancer control strategies., (© 2022 National Cancer Registrars Association.)
- Published
- 2022
3. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.
- Author
-
Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, Bonaventure A, Valkov M, Johnson CJ, Estève J, Ogunbiyi OJ, Azevedo E Silva G, Chen WQ, Eser S, Engholm G, Stiller CA, Monnereau A, Woods RR, Visser O, Lim GH, Aitken J, Weir HK, and Coleman MP
- Subjects
- Humans, Neoplasms pathology, Population Surveillance, Registries, Survival Rate, Neoplasms mortality
- Abstract
Background: In 2015, the second cycle of the CONCORD programme established global surveillance of cancer survival as a metric of the effectiveness of health systems and to inform global policy on cancer control. CONCORD-3 updates the worldwide surveillance of cancer survival to 2014., Methods: CONCORD-3 includes individual records for 37·5 million patients diagnosed with cancer during the 15-year period 2000-14. Data were provided by 322 population-based cancer registries in 71 countries and territories, 47 of which provided data with 100% population coverage. The study includes 18 cancers or groups of cancers: oesophagus, stomach, colon, rectum, liver, pancreas, lung, breast (women), cervix, ovary, prostate, and melanoma of the skin in adults, and brain tumours, leukaemias, and lymphomas in both adults and children. Standardised quality control procedures were applied; errors were rectified by the registry concerned. We estimated 5-year net survival. Estimates were age-standardised with the International Cancer Survival Standard weights., Findings: For most cancers, 5-year net survival remains among the highest in the world in the USA and Canada, in Australia and New Zealand, and in Finland, Iceland, Norway, and Sweden. For many cancers, Denmark is closing the survival gap with the other Nordic countries. Survival trends are generally increasing, even for some of the more lethal cancers: in some countries, survival has increased by up to 5% for cancers of the liver, pancreas, and lung. For women diagnosed during 2010-14, 5-year survival for breast cancer is now 89·5% in Australia and 90·2% in the USA, but international differences remain very wide, with levels as low as 66·1% in India. For gastrointestinal cancers, the highest levels of 5-year survival are seen in southeast Asia: in South Korea for cancers of the stomach (68·9%), colon (71·8%), and rectum (71·1%); in Japan for oesophageal cancer (36·0%); and in Taiwan for liver cancer (27·9%). By contrast, in the same world region, survival is generally lower than elsewhere for melanoma of the skin (59·9% in South Korea, 52·1% in Taiwan, and 49·6% in China), and for both lymphoid malignancies (52·5%, 50·5%, and 38·3%) and myeloid malignancies (45·9%, 33·4%, and 24·8%). For children diagnosed during 2010-14, 5-year survival for acute lymphoblastic leukaemia ranged from 49·8% in Ecuador to 95·2% in Finland. 5-year survival from brain tumours in children is higher than for adults but the global range is very wide (from 28·9% in Brazil to nearly 80% in Sweden and Denmark)., Interpretation: The CONCORD programme enables timely comparisons of the overall effectiveness of health systems in providing care for 18 cancers that collectively represent 75% of all cancers diagnosed worldwide every year. It contributes to the evidence base for global policy on cancer control. Since 2017, the Organisation for Economic Co-operation and Development has used findings from the CONCORD programme as the official benchmark of cancer survival, among their indicators of the quality of health care in 48 countries worldwide. Governments must recognise population-based cancer registries as key policy tools that can be used to evaluate both the impact of cancer prevention strategies and the effectiveness of health systems for all patients diagnosed with cancer., Funding: American Cancer Society; Centers for Disease Control and Prevention; Swiss Re; Swiss Cancer Research foundation; Swiss Cancer League; Institut National du Cancer; La Ligue Contre le Cancer; Rossy Family Foundation; US National Cancer Institute; and the Susan G Komen Foundation., (Copyright © 2018 Elsevier Ltd. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
4. Population-based cancer survival in the United States: Data, quality control, and statistical methods.
- Author
-
Allemani C, Harewood R, Johnson CJ, Carreira H, Spika D, Bonaventure A, Ward K, Weir HK, and Coleman MP
- Subjects
- Humans, United States epidemiology, Data Accuracy, Neoplasms mortality, Public Health Surveillance, Quality Control, Statistics as Topic
- Abstract
Background: Robust comparisons of population-based cancer survival estimates require tight adherence to the study protocol, standardized quality control, appropriate life tables of background mortality, and centralized analysis. The CONCORD program established worldwide surveillance of population-based cancer survival in 2015, analyzing individual data on 26 million patients (including 10 million US patients) diagnosed between 1995 and 2009 with 1 of 10 common malignancies., Methods: In this Cancer supplement, we analyzed data from 37 state cancer registries that participated in the second cycle of the CONCORD program (CONCORD-2), covering approximately 80% of the US population. Data quality checks were performed in 3 consecutive phases: protocol adherence, exclusions, and editorial checks. One-, 3-, and 5-year age-standardized net survival was estimated using the Pohar Perme estimator and state- and race-specific life tables of all-cause mortality for each year. The cohort approach was adopted for patients diagnosed between 2001 and 2003, and the complete approach for patients diagnosed between 2004 and 2009., Results: Articles in this supplement report population coverage, data quality indicators, and age-standardized 5-year net survival by state, race, and stage at diagnosis. Examples of tables, bar charts, and funnel plots are provided in this article., Conclusions: Population-based cancer survival is a key measure of the overall effectiveness of services in providing equitable health care. The high quality of US cancer registry data, 80% population coverage, and use of an unbiased net survival estimator ensure that the survival trends reported in this supplement are robustly comparable by race and state. The results can be used by policymakers to identify and address inequities in cancer survival in each state and for the United States nationally. Cancer 2017;123:4982-93. Published 2017. This article is a U.S. Government work and is in the public domain in the USA., (Published 2017. This article is a U.S. Government work and is in the public domain in the USA.)
- Published
- 2017
- Full Text
- View/download PDF
5. Worldwide comparison of survival from childhood leukaemia for 1995-2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries.
- Author
-
Bonaventure A, Harewood R, Stiller CA, Gatta G, Clavel J, Stefan DC, Carreira H, Spika D, Marcos-Gragera R, Peris-Bonet R, Piñeros M, Sant M, Kuehni CE, Murphy MFG, Coleman MP, and Allemani C
- Subjects
- Adolescent, Child, Child, Preschool, Female, Healthcare Disparities statistics & numerical data, Hematologic Neoplasms mortality, Humans, Infant, Infant, Newborn, Leukemia, Myeloid, Acute mortality, Male, Registries, Research Design, Healthcare Disparities trends, Neoplasms mortality, Precursor Cell Lymphoblastic Leukemia-Lymphoma mortality, Survival Analysis
- Abstract
Background: Global inequalities in access to health care are reflected in differences in cancer survival. The CONCORD programme was designed to assess worldwide differences and trends in population-based cancer survival. In this population-based study, we aimed to estimate survival inequalities globally for several subtypes of childhood leukaemia., Methods: Cancer registries participating in CONCORD were asked to submit tumour registrations for all children aged 0-14 years who were diagnosed with leukaemia between Jan 1, 1995, and Dec 31, 2009, and followed up until Dec 31, 2009. Haematological malignancies were defined by morphology codes in the International Classification of Diseases for Oncology, third revision. We excluded data from registries from which the data were judged to be less reliable, or included only lymphomas, and data from countries in which data for fewer than ten children were available for analysis. We also excluded records because of a missing date of birth, diagnosis, or last known vital status. We estimated 5-year net survival (ie, the probability of surviving at least 5 years after diagnosis, after controlling for deaths from other causes [background mortality]) for children by calendar period of diagnosis (1995-99, 2000-04, and 2005-09), sex, and age at diagnosis (<1, 1-4, 5-9, and 10-14 years, inclusive) using appropriate life tables. We estimated age-standardised net survival for international comparison of survival trends for precursor-cell acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML)., Findings: We analysed data from 89 828 children from 198 registries in 53 countries. During 1995-99, 5-year age-standardised net survival for all lymphoid leukaemias combined ranged from 10·6% (95% CI 3·1-18·2) in the Chinese registries to 86·8% (81·6-92·0) in Austria. International differences in 5-year survival for childhood leukaemia were still large as recently as 2005-09, when age-standardised survival for lymphoid leukaemias ranged from 52·4% (95% CI 42·8-61·9) in Cali, Colombia, to 91·6% (89·5-93·6) in the German registries, and for AML ranged from 33·3% (18·9-47·7) in Bulgaria to 78·2% (72·0-84·3) in German registries. Survival from precursor-cell ALL was very close to that of all lymphoid leukaemias combined, with similar variation. In most countries, survival from AML improved more than survival from ALL between 2000-04 and 2005-09. Survival for each type of leukaemia varied markedly with age: survival was highest for children aged 1-4 and 5-9 years, and lowest for infants (younger than 1 year). There was no systematic difference in survival between boys and girls., Interpretation: Global inequalities in survival from childhood leukaemia have narrowed with time but remain very wide for both ALL and AML. These results provide useful information for health policy makers on the effectiveness of health-care systems and for cancer policy makers to reduce inequalities in childhood cancer survival., Funding: Canadian Partnership Against Cancer, Cancer Focus Northern Ireland, Cancer Institute New South Wales, Cancer Research UK, US Centers for Disease Control and Prevention, Swiss Re, Swiss Cancer Research foundation, Swiss Cancer League, and the University of Kentucky., (Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
6. Life tables for global surveillance of cancer survival (the CONCORD programme): data sources and methods.
- Author
-
Spika D, Bannon F, Bonaventure A, Woods LM, Harewood R, Carreira H, Coleman MP, and Allemani C
- Subjects
- Aged, Aged, 80 and over, Female, Global Health, Humans, Japan epidemiology, Lesotho epidemiology, Life Expectancy, Life Tables, Male, Middle Aged, Mortality trends, Nigeria epidemiology, Population Surveillance, Registries, Neoplasms mortality
- Abstract
Background: We set out to estimate net survival trends for 10 common cancers in 279 cancer registry populations in 67 countries around the world, as part of the CONCORD-2 study. Net survival can be interpreted as the proportion of cancer patients who survive up to a given time, after eliminating the impact of mortality from other causes (background mortality). Background mortality varies widely between populations and over time. It was therefore necessary to construct robust life tables that accurately reflected the background mortality in each of the registry populations., Methods: Life tables of all-cause mortality rates by single year of age and sex were constructed by calendar year for each population and, when possible, by racial or ethnic sub-groups. We used three different approaches, based on the type of mortality data available from each registry. With death and population counts, we adopted a flexible multivariable modelling approach. With unsmoothed mortality rates, we used the Ewbank relational method. Where no data were available from the registry or a national statistical office, we used the abridged UN Population Division life tables and interpolated these using the Elandt-Johnson method. We also investigated the impact of using state- and race-specific life tables versus national race-specific life tables on estimates of net survival from four adult cancers in the United States (US)., Results: We constructed 6,514 life tables covering 327 populations. Wide variations in life expectancy at birth and mortality by age were observed, even within countries. During 1995-99, life expectancy was lowest in Nigeria and highest in Japan, ranging from 47 to 84 years among females and 46 to 78 years among males. During 2005-09, life expectancy was lowest in Lesotho and again highest in Japan, ranging from 45 to 86 years among females and 45 to 80 years among males. For the US, estimates of net survival differed by up to 4% if background mortality was fully controlled with state- and race-specific life tables, rather than with national race-specific life tables., Conclusions: Background mortality varies worldwide. This emphasises the importance of using population-specific life tables for geographic and international comparisons of net survival.
- Published
- 2017
- Full Text
- View/download PDF
7. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2).
- Author
-
Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, Bannon F, Ahn JV, Johnson CJ, Bonaventure A, Marcos-Gragera R, Stiller C, Azevedo e Silva G, Chen WQ, Ogunbiyi OJ, Rachet B, Soeberg MJ, You H, Matsuda T, Bielska-Lasota M, Storm H, Tucker TC, and Coleman MP
- Subjects
- Adolescent, Adult, Age Distribution, Aged, Aged, 80 and over, Child, Child, Preschool, Female, Global Health, Humans, Infant, Infant, Newborn, Male, Middle Aged, Registries, Sex Distribution, Survival Analysis, Young Adult, Neoplasms mortality
- Abstract
Background: Worldwide data for cancer survival are scarce. We aimed to initiate worldwide surveillance of cancer survival by central analysis of population-based registry data, as a metric of the effectiveness of health systems, and to inform global policy on cancer control., Methods: Individual tumour records were submitted by 279 population-based cancer registries in 67 countries for 25·7 million adults (age 15-99 years) and 75,000 children (age 0-14 years) diagnosed with cancer during 1995-2009 and followed up to Dec 31, 2009, or later. We looked at cancers of the stomach, colon, rectum, liver, lung, breast (women), cervix, ovary, and prostate in adults, and adult and childhood leukaemia. Standardised quality control procedures were applied; errors were corrected by the registry concerned. We estimated 5-year net survival, adjusted for background mortality in every country or region by age (single year), sex, and calendar year, and by race or ethnic origin in some countries. Estimates were age-standardised with the International Cancer Survival Standard weights., Findings: 5-year survival from colon, rectal, and breast cancers has increased steadily in most developed countries. For patients diagnosed during 2005-09, survival for colon and rectal cancer reached 60% or more in 22 countries around the world; for breast cancer, 5-year survival rose to 85% or higher in 17 countries worldwide. Liver and lung cancer remain lethal in all nations: for both cancers, 5-year survival is below 20% everywhere in Europe, in the range 15-19% in North America, and as low as 7-9% in Mongolia and Thailand. Striking rises in 5-year survival from prostate cancer have occurred in many countries: survival rose by 10-20% between 1995-99 and 2005-09 in 22 countries in South America, Asia, and Europe, but survival still varies widely around the world, from less than 60% in Bulgaria and Thailand to 95% or more in Brazil, Puerto Rico, and the USA. For cervical cancer, national estimates of 5-year survival range from less than 50% to more than 70%; regional variations are much wider, and improvements between 1995-99 and 2005-09 have generally been slight. For women diagnosed with ovarian cancer in 2005-09, 5-year survival was 40% or higher only in Ecuador, the USA, and 17 countries in Asia and Europe. 5-year survival for stomach cancer in 2005-09 was high (54-58%) in Japan and South Korea, compared with less than 40% in other countries. By contrast, 5-year survival from adult leukaemia in Japan and South Korea (18-23%) is lower than in most other countries. 5-year survival from childhood acute lymphoblastic leukaemia is less than 60% in several countries, but as high as 90% in Canada and four European countries, which suggests major deficiencies in the management of a largely curable disease., Interpretation: International comparison of survival trends reveals very wide differences that are likely to be attributable to differences in access to early diagnosis and optimum treatment. Continuous worldwide surveillance of cancer survival should become an indispensable source of information for cancer patients and researchers and a stimulus for politicians to improve health policy and health-care systems., Funding: Canadian Partnership Against Cancer (Toronto, Canada), Cancer Focus Northern Ireland (Belfast, UK), Cancer Institute New South Wales (Sydney, Australia), Cancer Research UK (London, UK), Centers for Disease Control and Prevention (Atlanta, GA, USA), Swiss Re (London, UK), Swiss Cancer Research foundation (Bern, Switzerland), Swiss Cancer League (Bern, Switzerland), and University of Kentucky (Lexington, KY, USA)., (Copyright © 2015 Allemani et al. Open Access article distributed under the terms of CC BY. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
8. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries
- Author
-
Allemani, C, Matsuda, T, Di Carlo, V, Harewood, R, Matz, M, Nikšić, M, Bonaventure, A, Valkov, M, Johnson, CJ, Estève, J, Ogunbiyi, OJ, Azevedo e Silva, G, Chen, WQ, Eser, S, Engholm, G, Stiller, CA, Monnereau, A, Woods, RR, Visser, O, Lim, GH, Aitken, J, Weir, HK, Coleman, MP, Bouzbid, S, Hamdi-Chérif, M, Zaidi, Z, Meguenni, K, Regagba, D, Bayo, S, Cheick Bougadari, T, Manraj, SS, Bendahhou, K, Fabowale, A, Bradshaw, D, Somdyala, NIM, Kumcher, I, Moreno, F, Calabrano, GH, Espinola, SB, Carballo Quintero, B, Fita, R, Diumenjo, MC, Laspada, WD, Ibañez, SG, Lima, CA, De Souza, PCF, Del Pino, K, Laporte, C, Curado, MP, de Oliveira, JC, Veneziano, CLA, Veneziano, DB, Latorre, MRDO, Tanaka, LF, Rebelo, MS, Santos, MO, Galaz, JC, Aparicio Aravena, M, Sanhueza Monsalve, J, Herrmann, DA, Vargas, S, Herrera, VM, Uribe, CJ, Bravo, LE, Garcia, LS, Arias-Ortiz, NE, Morantes, D, Jurado, DM, Yépez Chamorro, MC, Delgado, S, Ramirez, M, Galán Alvarez, YH, Torres, P, Martínez-Reyes, F, Jaramillo, L, Quinto, R, Castillo, J, Mendoza, M, Cueva, P, Yépez, JG, Bhakkan, B, Deloumeaux, J, Joachim, C, Macni, J, Carrillo, R, Shalkow Klincovstein, J, Rivera Gomez, R, Poquioma, E, Tortolero-Luna, G, Zavala, D, Alonso, R, Barrios, E, Eckstrand, A, Nikiforuk, C, Noonan, G, Turner, D, Kumar, E, Zhang, B, McCrate, FR, and Ryan, S
- Subjects
Survival Rate ,General & Internal Medicine ,Neoplasms ,Population Surveillance ,Humans ,Registries - Abstract
© 2018 Elsevier Ltd Background: In 2015, the second cycle of the CONCORD programme established global surveillance of cancer survival as a metric of the effectiveness of health systems and to inform global policy on cancer control. CONCORD-3 updates the worldwide surveillance of cancer survival to 2014. Methods: CONCORD-3 includes individual records for 37·5 million patients diagnosed with cancer during the 15-year period 2000–14. Data were provided by 322 population-based cancer registries in 71 countries and territories, 47 of which provided data with 100% population coverage. The study includes 18 cancers or groups of cancers: oesophagus, stomach, colon, rectum, liver, pancreas, lung, breast (women), cervix, ovary, prostate, and melanoma of the skin in adults, and brain tumours, leukaemias, and lymphomas in both adults and children. Standardised quality control procedures were applied; errors were rectified by the registry concerned. We estimated 5-year net survival. Estimates were age-standardised with the International Cancer Survival Standard weights. Findings: For most cancers, 5-year net survival remains among the highest in the world in the USA and Canada, in Australia and New Zealand, and in Finland, Iceland, Norway, and Sweden. For many cancers, Denmark is closing the survival gap with the other Nordic countries. Survival trends are generally increasing, even for some of the more lethal cancers: in some countries, survival has increased by up to 5% for cancers of the liver, pancreas, and lung. For women diagnosed during 2010–14, 5-year survival for breast cancer is now 89·5% in Australia and 90·2% in the USA, but international differences remain very wide, with levels as low as 66·1% in India. For gastrointestinal cancers, the highest levels of 5-year survival are seen in southeast Asia: in South Korea for cancers of the stomach (68·9%), colon (71·8%), and rectum (71·1%); in Japan for oesophageal cancer (36·0%); and in Taiwan for liver cancer (27·9%). By contrast, in the same world region, survival is generally lower than elsewhere for melanoma of the skin (59·9% in South Korea, 52·1% in Taiwan, and 49·6% in China), and for both lymphoid malignancies (52·5%, 50·5%, and 38·3%) and myeloid malignancies (45·9%, 33·4%, and 24·8%). For children diagnosed during 2010–14, 5-year survival for acute lymphoblastic leukaemia ranged from 49·8% in Ecuador to 95·2% in Finland. 5-year survival from brain tumours in children is higher than for adults but the global range is very wide (from 28·9% in Brazil to nearly 80% in Sweden and Denmark). Interpretation: The CONCORD programme enables timely comparisons of the overall effectiveness of health systems in providing care for 18 cancers that collectively represent 75% of all cancers diagnosed worldwide every year. It contributes to the evidence base for global policy on cancer control. Since 2017, the Organisation for Economic Co-operation and Development has used findings from the CONCORD programme as the official benchmark of cancer survival, among their indicators of the quality of health care in 48 countries worldwide. Governments must recognise population-based cancer registries as key policy tools that can be used to evaluate both the impact of cancer prevention strategies and the effectiveness of health systems for all patients diagnosed with cancer. Funding: American Cancer Society; Centers for Disease Control and Prevention; Swiss Re; Swiss Cancer Research foundation; Swiss Cancer League; Institut National du Cancer; La Ligue Contre le Cancer; Rossy Family Foundation; US National Cancer Institute; and the Susan G Komen Foundation.
- Published
- 2017
9. The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2)
- Author
-
Matz, Melissa, Coleman, Michel P, Sant, Milena, Chirlaque, Maria Dolores, Visser, Otto, Gore, Martin, Allemani, Claudia, Bouzbid, S, Hamdi-chérif, M, Zaidi, Z, Bah, E, Swaminathan, R, Nortje, Sh, El Mistiri, Mm, Bayo, S, Malle, B, Manraj, Ss, Sewpaul-sungkur, R, Fabowale, A, Ogunbiyi, Oj, Bradshaw, D, Somdyala, Nim, Stefan, Dc, Abdel-rahman, M, Jaidane, L, Mokni, M, Kumcher, I, Moreno, F, González, Ms, Laura, Ea, Espinola, Sb, Calabrano, Gh, Carballo Quintero, B, Fita, R, Garcilazo, Da, Giacciani, Pl, Diumenjo, Mc, Laspada, Wd, Green, Ma, Lanza, Mf, Ibañez, Sg, Lima, Ca, Lobo De Oliveira, E, Daniel, C, Scandiuzzi, C, De Souza, Pcf, Melo, Cd, Del Pino, K, Laporte, C, Curado, Mp, De Oliveira, Jc, Veneziano, Cla, Veneziano, Db, Latorre, Mrdo, Tanaka, Lf, Azevedo E. Silva, G, Galaz, Jc, Moya, Ja, Herrmann, Da, Vargas, S, Herrera, Vm, Uribe, Cj, Bravo, Le, Arias-ortiz, Ne, Jurado, Dm, Yépez, Mc, Galán, Yh, Torres, P, Martínez-reyes, F, Pérez-meza, Ml, Jaramillo, L, Quinto, R, Cueva, P, Yépez, Jg, Torres-cintrón, Cr, Tortolero-luna, G, Alonso, R, Barrios, E, Nikiforuk, C, Shack, L, Coldman, Aj, Woods, Rr, Noonan, G, Turner, D, Kumar, E, Zhang, B, Mccrate, Fr, Ryan, S, Hannah, H, Dewar, Rad, Macintyre, M, Lalany, A, Ruta, M, Marrett, L, Nishri, De, Mcclure, C, Vriends, Ka, Bertrand, C, Louchini, R, Robb, K, Stuart-panko, H, Demers, S, Wright, S, George, Jt, Shen, X, Brockhouse, Jt, O'brien, Dk, Ward, Kc, Almon, L, Bates, J, Rycroft, R, Mueller, L, Phillips, C, Brown, H, Cromartie, B, Schwartz, Ag, Vigneau, F, Mackinnon, Ja, Wohler, B, Bayakly, Ar, Clarke, Ca, Glaser, Sl, West, D, Green, Md, Hernandez, By, Johnson, Cj, Jozwik, D, Charlton, Me, Lynch, Cf, Huang, B, Tucker, Tc, Deapen, D, Liu, L, Hsieh, Mc, Wu, Xc, Stern, K, Gershman, St, Knowlton, Rc, Alverson, J, Copeland, Ge, Rogers, Db, Lemons, D, Williamson, Ll, Hood, M, Hosain, Gm, Rees, Jr, Pawlish, Ks, Stroup, A, Key, C, Wiggins, C, Kahn, Ar, Schymura, Mj, Leung, G, Rao, C, Giljahn, L, Warther, B, Pate, A, Patil, M, Schubert, Ss, Rubertone, Jj, Slack, Sj, Fulton, Jp, Rousseau, Dl, Janes, Ta: Schwartz, Bolick, Sw, Hurley, Dm, Richards, J, Whiteside, Ma, Nogueira, Lm, Herget, K, Sweeney, C, Martin, J, Wang, S, Harrelson, Dg, Keitheri Cheteri, Mb, Farley, S, Hudson, Ag, Borchers, R, Stephenson, L, Espinoza, Jr, Weir, Hk, Edwards, Bk, Wang, N, Yang, L, Chen, Js, Song, Gh, Gu, Xp, Zhang, P, Ge, Hm, Zhao, Dl, Zhang, Jh, Zhu, Fd, Tang, Jg, Shen, Y, Wang, J, Li, Ql, Yang, Xp, Dong, J, Li, W, Cheng, Lp, Chen, Jg, Huang, Qh, Huang, Sq, Guo, Gp, Wei, K, Chen, Wq, Zeng, H, Demetriou, Av, Pavlou, P, Mang, Wk, Ngan, Kc, Kataki, Ac, Krishnatreya, M, Jayalekshmi, Pa, Sebastian, P, Sapkota, Sd, Verma, Y, Nandakumar, A, Suzanna, E, Keinan-boker, L, Silverman, Bg, Ito, H, Nakagawa, H, Hattori, M, Kaizaki, Y, Sugiyama, H, Utada, M, Katayama, K, Narimatsu, H, Kanemura, S, Koike, T, Miyashiro, I, Yoshii, M, Oki, I, Shibata, A, Matsuda, T, Nimri, O, Ab Manan, A, Bhoo-pathy, N, Tuvshingerel, S, Chimedsuren, O, Al Khater, Ahm, Al-eid, H, Jung, Kw, Won, Yj, Chiang, Cj, Lai, Ms, Suwanrungruang, K, Wiangnon, S, Daoprasert, K, Pongnikorn, D, Geater, Sl, Sriplung, H, Eser, S, Yakut, Ci, Hackl, M, Mühlböck, H, Oberaigner, W, Zborovskaya, Aa, Aleinikova, Ov, Henau, K, Van Eycken, L, Dimitrova, N, Valerianova, Z, Šekerija, M, Zvolský, M, Engholm, G, Storm, H, Innos, K, Mägi, M, Malila, N, Seppä, K, Jégu, J, Velten, M, Cornet, E, Troussard, X, Bouvier, Am, Faivre, J, Guizard, Av, Bouvier, V, Launoy, G, Arveux, P, Maynadié, M, Mounier, M, Fournier, E, Woronoff, As, Daoulas, M, Clavel, J, Le Guyader-peyrou, S, Monnereau, A, Trétarre, B, Colonna, M, Cowppli-bony, A, Molinié, F, Bara, S, Degré, D, Ganry, O, Lapôtre-ledoux, B, Grosclaude, P, Estève, J, Bray, F, Piñeros, M, Sassi, F, Stabenow, R, Eberle, A, Erb, C, Nennecke, A, Kieschke, J, Sirri, E, Kajueter, H, Emrich, K, Zeissig, Sr, Holleczek, B, Eisemann, N, Katalinic, A, Brenner, H, Asquez, Ra, Kumar, V, Ólafsdóttir, Ej, Tryggvadóttir, L, Comber, H, Walsh, Pm, Sundseth, H, Devigili, E, Mazzoleni, G, Giacomin, A, DI BELLA, Francesca, Castaing, M, Sutera, A, Gola, G, Ferretti, S, Serraino, D, Zucchetto, A, Lillini, R, Vercelli, M, Busco, S, Pannozzo, F, Vitarelli, S, Ricci, P, Pascucci, C, Autelitano, M, Cirilli, C, Federico, M, FUSCO, Elena Maria, Vitale, Mf, Usala, M, Cusimano, R, Mazzucco, W, Michiara, M, Sgargi, P, Maule, Mm, Sacerdote, C, Tumino, R, Di Felice, E, Vicentini, M, Falcini, F, Cremone, L, Budroni, M, Cesaraccio, R, Contrino, Ml, Tisano, F, Fanetti, Ac, Maspero, S, Candela, G, Scuderi, T, Gentilini, Ma, Piffer, S, Rosso, S, Sacchetto, L, Caldarella, A, La Rosa, F, Stracci, F, Contiero, P, Tagliabue, G, Dei Tos, Ap, Zorzi, M, Zanetti, R, Baili, P, Berrino, F, Gatta, G, Sant, M, Capocaccia, R, De Angelis, R, Liepina, E, Maurina, A, Smailyte, G, Agius, D, Calleja, N, Siesling, S, Visser, O, Larønningen, S, Møller, B, Dyzmann-sroka, A, Trojanowski, M, Góźdż, S, Mężyk, R, Grądalska-lampart, M, Radziszewska, Au, Didkowska, Ja, Wojciechowska, U, Błaszczyk, J, Kępska, K, Bielska-lasota, M, Kwiatkowska, K, Forjaz, G, Rego, Ra, Bastos, J, Silva, Ma, Antunes, L, Bento, Mj, Mayer-da-silva, A, Miranda, A, Coza, D, Todescu, Ai, Valkov, My, Adamcik, J, Safaei Diba, C, Primic-žakelj, M, Žagar, T, Stare, J, Almar, E, Mateos, A, Quirós, Jr, Bidaurrazaga, J, Larrañaga, N, Díaz García, Jm, Marcos, Ai, Marcos-gragera, R, Vilardell Gil, Ml, Molina, E, Sánchez, Mj, Franch Sureda, P, Ramos Montserrat, M, Chirlaque, Md, Navarro, C, Ardanaz, Ee, Moreno-iribas, Cc, Fernández-delgado, R, Peris-bonet, R, Galceran, J, Khan, S, Lambe, M, Camey, B, Bouchardy, C, Usel, M, Ess, Sm, Herrmann, C, Bulliard, Jl, Maspoli-conconi, M, Frick, H, Kuehni, Ce, Schindler, M, Bordoni, A, Spitale, A, Chiolero, A, Konzelmann, I, Dehler, Si, Matthes, Kl, Rashbass, J, Stiller, Ca, Fitzpatrick, D, Gavin, A, Bannon, F, Black, Rj, Brewster, Dh, Huws, Dw, White, C, Finan, P, Allemani, C, Bonaventure, A, Carreira, H, Coleman, Mp, Di Carlo, V, Harewood, R, Liu, K, Matz, M, Montel, L, Nikšić, M, Rachet, B, Sanz, N, Spika, D, Stephens, R, Peake, M, Chalker, E, Newman, L, Baker, D, Soeberg, Mj, Aitken, J, Scott, C, Stokes, Bc, Venn, A, Farrugia, H, Giles, Gg, Threlfall, T, Currow, D, You, H, Hendrix, J, Lewis, C., Matz, M., Coleman, M., Sant, M., Chirlaque, M., Visser, O., Gore, M., Allemani, C., Bouzbid, S., Hamdi-chérif, M., Zaidi, Z., Bah, E., Swaminathan, R., Nortje, S., El Mistiri, M., Bayo, S., Malle, B., Manraj, S., Sewpaul-sungkur, R., Fabowale, A., Ogunbiyi, O., Bradshaw, D., Somdyala, N., Stefan, D., Abdel-rahman, M., Jaidane, L., Mokni, M., Kumcher, I., Moreno, F., González, M., Laura, E., Espinola, S., Calabrano, G., Carballo Quintero, B., Fita, R., Garcilazo, D., Giacciani, P., Diumenjo, M., Laspada, W., Green, M., Lanza, M., Ibañez, S., Lima, C., Lobo De Oliveira, E., Daniel, C., Scandiuzzi, C., De Souza, P., Melo, C., Del Pino, K., Laporte, C., Curado, M., De Oliveira, J., Veneziano, C., Veneziano, D., Latorre, M., Tanaka, L., Azevedo E. Silva, G., Galaz, J., Moya, J., Herrmann, D., Vargas, S., Herrera, V., Uribe, C., Bravo, L., Arias-ortiz, N., Jurado, D., Yépez, M., Galán, Y., Torres, P., Martínez-reyes, F., Pérez-meza, M., Jaramillo, L., Quinto, R., Cueva, P., Yépez, J., Torres-cintrón, C., Tortolero-luna, G., Alonso, R., Barrios, E., Nikiforuk, C., Shack, L., Coldman, A., Woods, R., Noonan, G., Turner, D., Kumar, E., Zhang, B., Mccrate, F., Ryan, S., Hannah, H., Dewar, R., Macintyre, M., Lalany, A., Ruta, M., Marrett, L., Nishri, D., Mcclure, C., Vriends, K., Bertrand, C., Louchini, R., Robb, K., Stuart-panko, H., Demers, S., Wright, S., George, J., Shen, X., Brockhouse, J., O'Brien, D., Ward, K., Almon, L., Bates, J., Rycroft, R., Mueller, L., Phillips, C., Brown, H., Cromartie, B., Schwartz, A., Vigneau, F., Mackinnon, J., Wohler, B., Bayakly, A., Clarke, C., Glaser, S., West, D., Hernandez, B., Johnson, C., Jozwik, D., Charlton, M., Lynch, C., Huang, B., Tucker, T., Deapen, D., Liu, L., Hsieh, M., Xc, W., Stern, K., Gershman, S., Knowlton, R., Alverson, J., Copeland, G., Rogers, D., Lemons, D., Williamson, L., Hood, M., Hosain, G., Rees, J., Pawlish, K., Stroup, A., Key, C., Wiggins, C., Kahn, A., Schymura, M., Leung, G., Rao, C., Giljahn, L., Warther, B., Pate, A., Patil, M., Schubert, S., Rubertone, J., Slack, S., Fulton, J., Rousseau, D., Janes, Ta:, S., Sm, Bolick, S., Hurley, D., Richards, J., Whiteside, M., Nogueira, L., Herget, K., Sweeney, C., Martin, J., Wang, S., Harrelson, D., Keitheri Cheteri, M., Farley, S., Hudson, A., Borchers, R., Stephenson, L., Espinoza, J., Weir, H., Edwards, B., Wang, N., Yang, L., Chen, J., Song, G., Xp, G., Zhang, P., Hm, G., Zhao, D., Zhang, J., Zhu, F., Tang, J., Shen, Y., Wang, J., Ql, L., Yang, X., Dong, J., Li, W., Cheng, L., Huang, Q., Huang, S., Guo, G., Wei, K., Chen, W., Zeng, H., Demetriou, A., Pavlou, P., Mang, W., Ngan, K., Kataki, A., Krishnatreya, M., Jayalekshmi, P., Sebastian, P., Sapkota, S., Verma, Y., Nandakumar, A., Suzanna, E., Keinan-boker, L., Silverman, B., Ito, H., Nakagawa, H., Hattori, M., Kaizaki, Y., Sugiyama, H., Utada, M., Katayama, K., Narimatsu, H., Kanemura, S., Koike, T., Miyashiro, I., Yoshii, M., Oki, I., Shibata, A., Matsuda, T., Nimri, O., Ab Manan, A., Bhoo-pathy, N., Tuvshingerel, S., Chimedsuren, O., Al Khater, A., Al-eid, H., Jung, K., Won, Y., Chiang, C., Lai, M., Suwanrungruang, K., Wiangnon, S., Daoprasert, K., Pongnikorn, D., Geater, S., Sriplung, H., Eser, S., Yakut, C., Hackl, M., Mühlböck, H., Oberaigner, W., Zborovskaya, A., Aleinikova, O., Henau, K., Van Eycken, L., Dimitrova, N., Valerianova, Z., Šekerija, M., Zvolský, M., Engholm, G., Storm, H., Innos, K., Mägi, M., Malila, N., Seppä, K., Jégu, J., Velten, M., Cornet, E., Troussard, X., Bouvier, A., Faivre, J., Guizard, A., Bouvier, V., Launoy, G., Arveux, P., Maynadié, M., Mounier, M., Fournier, E., Woronoff, A., Daoulas, M., Clavel, J., Le Guyader-peyrou, S., Monnereau, A., Trétarre, B., Colonna, M., Cowppli-bony, A., Molinié, F., Bara, S., Degré, D., Ganry, O., Lapôtre-ledoux, B., Grosclaude, P., Estève, J., Bray, F., Piñeros, M., Sassi, F., Stabenow, R., Eberle, A., Erb, C., Nennecke, A., Kieschke, J., Sirri, E., Kajueter, H., Emrich, K., Zeissig, S., Holleczek, B., Eisemann, N., Katalinic, A., Brenner, H., Asquez, R., Kumar, V., Ólafsdóttir, E., Tryggvadóttir, L., Comber, H., Walsh, P., Sundseth, H., Devigili, E., Mazzoleni, G., Giacomin, A., DI BELLA, F., Castaing, M., Sutera, A., Gola, G., Ferretti, S., Serraino, D., Zucchetto, A., Lillini, R., Vercelli, M., Busco, S., Pannozzo, F., Vitarelli, S., Ricci, P., Pascucci, C., Autelitano, M., Cirilli, C., Federico, M., Fusco, E., Vitale, M., Usala, M., Cusimano, R., Mazzucco, W., Michiara, M., Sgargi, P., Maule, M., Sacerdote, C., Tumino, R., Di Felice, E., Vicentini, M., Falcini, F., Cremone, L., Budroni, M., Cesaraccio, R., Contrino, M., Tisano, F., Fanetti, A., Maspero, S., Candela, G., Scuderi, T., Gentilini, M., Piffer, S., Rosso, S., Sacchetto, L., Caldarella, A., La Rosa, F., Stracci, F., Contiero, P., Tagliabue, G., Dei Tos, A., Zorzi, M., Zanetti, R., Baili, P., Berrino, F., Gatta, G., Capocaccia, R., De Angelis, R., Liepina, E., Maurina, A., Smailyte, G., Agius, D., Calleja, N., Siesling, S., Larønningen, S., Møller, B., Dyzmann-sroka, A., Trojanowski, M., Góźdż, S., Mężyk, R., Grądalska-lampart, M., Radziszewska, A., Didkowska, J., Wojciechowska, U., Błaszczyk, J., Kępska, K., Bielska-lasota, M., Kwiatkowska, K., Forjaz, G., Rego, R., Bastos, J., Silva, M., Antunes, L., Bento, M., Mayer-da-silva, A., Miranda, A., Coza, D., Todescu, A., Valkov, M., Adamcik, J., Safaei Diba, C., Primic-žakelj, M., Žagar, T., Stare, J., Almar, E., Mateos, A., Quirós, J., Bidaurrazaga, J., Larrañaga, N., Díaz García, J., Marcos, A., Marcos-gragera, R., Vilardell Gil, M., Molina, E., Sánchez, M., Franch Sureda, P., Ramos Montserrat, M., Navarro, C., Ardanaz, E., Moreno-iribas, C., Fernández-delgado, R., Peris-bonet, R., Galceran, J., Khan, S., Lambe, M., Camey, B., Bouchardy, C., Usel, M., Ess, S., Herrmann, C., Bulliard, J., Maspoli-conconi, M., Frick, H., Kuehni, C., Schindler, M., Bordoni, A., Spitale, A., Chiolero, A., Konzelmann, I., Dehler, S., Matthes, K., Rashbass, J., Stiller, C., Fitzpatrick, D., Gavin, A., Bannon, F., Black, R., Brewster, D., Huws, D., White, C., Finan, P., Bonaventure, A., Carreira, H., Di Carlo, V., Harewood, R., Liu, K., Montel, L., Nikšić, M., Rachet, B., Sanz, N., Spika, D., Stephens, R., Peake, M., Chalker, E., Newman, L., Baker, D., Soeberg, M., Aitken, J., Scott, C., Stokes, B., Venn, A., Farrugia, H., Giles, G., Threlfall, T., Currow, D., You, H., Hendrix, J., and Lewis, C.
- Subjects
Epidemiology ,Histology ,Morphology ,Ovarain cancer ,Worldwide ,0301 basic medicine ,Oncology ,Pathology ,endocrine system diseases ,Sex Cord-Gonadal Stromal Tumors ,Carcinoma, Ovarian Epithelial ,0302 clinical medicine ,Neoplasms ,Neoplasms, Glandular and Epithelial ,Ovarian Neoplasms ,education.field_of_study ,Adolescent ,Adult ,Aged ,Female ,Humans ,Middle Aged ,Neoplasms, Germ Cell and Embryonal ,Obstetrics and Gynecology ,Glandular and Epithelial ,female genital diseases and pregnancy complications ,Transitional cell carcinoma ,030220 oncology & carcinogenesis ,Clear cell carcinoma ,Human ,endocrine system ,medicine.medical_specialty ,Population ,Socio-culturale ,03 medical and health sciences ,Internal medicine ,medicine ,education ,Mixed tumor ,business.industry ,Ovarian Neoplasm ,Sex Cord-Gonadal Stromal Tumor ,medicine.disease ,030104 developmental biology ,Germ Cell and Embryonal ,Ovarian cancer ,business - Abstract
OBJECTIVE: Ovarian cancers comprise several histologically distinct tumour groups with widely different prognosis. We aimed to describe the worldwide distribution of ovarian cancer histology and to understand what role this may play in international variation in survival. METHODS: The CONCORD programme is the largest population-based study of global trends in cancer survival. Data on 681,759 women diagnosed during 1995-2009 with cancer of the ovary, fallopian tube, peritoneum and retroperitonum in 51 countries were included. We categorised ovarian tumours into six histological groups, and explored the worldwide distribution of histology. RESULTS: During 2005-2009, type II epithelial tumours were the most common. The proportion was much higher in Oceania (73.1%), North America (73.0%) and Europe (72.6%) than in Central and South America (65.7%) and Asia (56.1%). By contrast, type I epithelial tumours were more common in Asia (32.5%), compared with only 19.4% in North America. From 1995 to 2009, the proportion of type II epithelial tumours increased from 68.6% to 71.1%, while the proportion of type I epithelial tumours fell from 23.8% to 21.2%. The proportions of germ cell tumours, sex cord-stromal tumours, other specific non-epithelial tumours and tumours of non-specific morphology all remained stable over time. CONCLUSIONS: The distribution of ovarian cancer histology varies widely worldwide. Type I epithelial, germ cell and sex cord-stromal tumours are generally associated with higher survival than type II tumours, so the proportion of these tumours may influence survival estimates for all ovarian cancers combined. The distribution of histological groups should be considered when comparing survival between countries and regions.
- Published
- 2016
10. Worldwide comparison of survival from childhood leukaemia for 1995–2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries
- Author
-
Bonaventure, A, Harewood, R, Stiller, CA, Gatta, G, Clavel, J, Stefan, DC, Carreira, H, Spika, D, Marcos-Gragera, R, Peris-Bonet, R, Piñeros, M, Sant, M, Kuehni, CE, Murphy, MFG, Coleman, MP, Allemani, C, Bouzbid, S, Hamdi-Chérif, M, Zaidi, Z, Bah, E, Swaminathan, R, Nortje, SH, El Mistiri, MM, Bayo, S, Malle, B, Manraj, SS, Sewpaul-Sungkur, R, Fabowale, Bradshaw, D, Somdyala, NIM, Abdel-Rahman, M, Jaidane, L, Mokni, M, Kumcher, I, Moreno, F, González, MS, Laura, EA, Espinola, SB, Calabrano, GH, Carballo Quintero, B, Fita, R, Garcilazo, DA, Giacciani, PL, Diumenjo, MC, Laspada, WD, Green, MA, Lanza, MF, Ibañez, SG, Lima, CA, de Oliveira, EL, Daniel, C, Scandiuzzi, C, De Souza, PCF, Melo, CD, Del Pino, K, Laporte, C, Curado, MP, de Oliveira, JC, Veneziano, CLA, Veneziano, DB, Alexandre, TS, Verdugo, AS, Azevedo e Silva, G, Galaz, JC, Moya, JA, Herrmann, DA, Vargas, S, Herrera, VM, Uribe, CJ, Bravo, LE, Arias-Ortiz, NE, Jurado, DM, Yépez, MC, Galán, YH, Torres, P, Martínez-Reyes, F, Pérez-Meza, ML, Jaramillo, L, Quinto, R, Cueva, P, Yépez, JG, Torres-Cintrón, CR, Tortolero-Luna, G, Alonso, R, Barrios, E, Nikiforuk, C, Shack, L, Coldman, AJ, Woods, RR, Noonan, G, Turner, D, Kumar, E, Zhang, B, McCrate, FR, Ryan, S, Hannah, H, Dewar, RAD, MacIntyre, M, Lalany, A, and Ruta, M
- Subjects
Male ,Adolescent ,Infant, Newborn ,Infant ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Survival Analysis ,Leukemia, Myeloid, Acute ,Research Design ,Neoplasms ,Hematologic Neoplasms ,Child, Preschool ,Humans ,Female ,Registries ,Healthcare Disparities ,Child - Abstract
© 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license Background Global inequalities in access to health care are reflected in differences in cancer survival. The CONCORD programme was designed to assess worldwide differences and trends in population-based cancer survival. In this population-based study, we aimed to estimate survival inequalities globally for several subtypes of childhood leukaemia. Methods Cancer registries participating in CONCORD were asked to submit tumour registrations for all children aged 0–14 years who were diagnosed with leukaemia between Jan 1, 1995, and Dec 31, 2009, and followed up until Dec 31, 2009. Haematological malignancies were defined by morphology codes in the International Classification of Diseases for Oncology, third revision. We excluded data from registries from which the data were judged to be less reliable, or included only lymphomas, and data from countries in which data for fewer than ten children were available for analysis. We also excluded records because of a missing date of birth, diagnosis, or last known vital status. We estimated 5-year net survival (ie, the probability of surviving at least 5 years after diagnosis, after controlling for deaths from other causes [background mortality]) for children by calendar period of diagnosis (1995–99, 2000–04, and 2005–09), sex, and age at diagnosis (
- Published
- 2017
11. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)
- Author
-
Allemani, Claudia, Weir, Hannah K., Carreira, Helena, Harewood, Rhea, Spika, Devon, Wang, Xiao-Si, Bannon, Finian, Ahn, Jane V, Johnson, Christopher J., Bonaventure, Audrey, Marcos-Gragera, Rafael, Stiller, Charles, Azevedo E Silva, Gulnar, Chen, Wan-Qing, Ogunbiyi, Olufemi J., Rachet, Bernard, Soeberg, Matthew J, You, Hui, Matsuda, Tomohiro, Bielska-Lasota, Magdalena, Storm, Hans, Tucker, Thomas C., Coleman, Michel, P, CONCORD Working Group (Bouzbid, S, Hamdi-Chérif, M, Zaidi, Z, Bah, E, Swaminathan, R, Nortje, Sh, Stefan, Cd, El Mistiri MM, Bayo, S, Malle, B, Manraj, Ss, Sewpaul-Sungkur, R, Fabowale, A, Ogunbiyi, Oj, Bradshaw, D, Somdyala, Ni, Abdel-Rahman, M, Jaidane, L, Mokni, M, Kumcher, I, Moreno, F, González, Ms, Laura, E, Pugh, Fv, Torrent, Me, Carballo Quintero, B, Fita, R, Garcilazo, D, Giacciani, Pl, Diumenjo, Mc, Laspada, Wd, Green, Ma, Lanza, Mf, Ibañez, Sg, Lima, Ca, Lobo, E, Daniel, C, Scandiuzzi, C, De Souza PC, Del Pino, K, Laporte, C, Curado, Mp, de Oliveira JC, Veneziano, Cl, Veneziano, Db, Alexandre, Ts, Verdugo, As, Koifman, S, e Silva G, Azevedo, Galaz, Jc, Moya, Ja, Herrmann, Da, Jofre, Am, Uribe, Cj, Bravo, Le, Lopez Guarnizo, G, Jurado, Dm, Yepes, Mc, Galán, Yh, Torres, P, Martínez-Reyes, F, Jaramillo, L, Quinto, R, Cueva, P, Yépez, J, Torres-Cintrón, Cr, Tortolero-Luna, G, Alonso, R, Barrios, E, Russell, C, Shack, L, Coldman, Aj, Woods, Rr, Noonan, G, Turner, D, Kumar, E, Zhang, B, Mccrate, Fr, Ryan, S, Hannah, H, Dewar, Ra, Macintyre, M, Lalany, A, Ruta, M, Marrett, L, Nishri, De, Vriends, Ka, Bertrand, C, Louchini, R, Robb, Ki, Stuart-Panko, H, Demers, S, Wright, S, George, J, Shen, X, Brockhouse, Jt, O'Brien, Dk, Almon, L, Young, Jl, Bates, J, Rycroft, R, Mueller, L, Phillips, C, Ryan, H, Walrath, J, Schwartz, A, Vigneau, F, Mackinnon, Ja, Wohler, B, Bayakly, R, Ward, Kc, Davidson-Allen, K, Glaser, S, West, D, Green, Md, Hernandez, By, Johnson, Cj, Lynch, Cf, Mckeen, Km, Huang, B, Tucker, Tc, Deapen, D, Liu, L, Hsieh, Mc, Wu, Xc, Stern, K, Gershman, St, Knowlton, Rc, Copeland, G, Spivak, G, Rogers, Db, Lemons, D, Williamson, Ll, Hood, M, Jerry, H, Hosain, Gm, Rees, Jr, Pawlish, Ks, Stroup, A, Key, C, Wiggins, C, Kahn, Ar, Schymura, Mj, Leung, G, Rao, C, Giljahn, L, Warther, B, Pate, A, Patil, M, Shipley, Dk, Esterly, M, Otto, Rd, Fulton, Jp, Rousseau, Dl, Janes, Ta, Schwartz, Sm, Bolick, Sw, Hurley, Dm, Tenney, Ra, Whiteside, Ma, Hakenewerth, A, Williams, Ma, Herget, K, Sweeney, C, Martin, J, Wang, S, Harrelson, Mg, Keitheri Cheteri MB, Hudson, Ag, Borchers, R, Stephenson, L, Espinoza, Jr, Weir, Hk, Edwards, Bk, Wang, N, Yang, L, Chen, Js, Song, Gh, Gu, Xp, Zhang, P, Ge, Hm, Zhao, Dl, Zhang, Jh, Zhu, Fd, Tang, Jg, Shen, Y, Wang, J, Li, Ql, Yang, Sp, Dong, Jm, Li, Ww, Cheng, Lp, Chen, Jg, Huang, Qh, Huang, Sq, Guo, Gp, Wei, K, Chen, Wq, Zeng, H, Demetriou, Aw, Pavlou, P, Mang, Wk, Ngan, Kc, Kataki, Ac, Krishnatreya, M, Jayalekshmi, Pa, Sebastian, P, Sapkota, Sd, Verma, Y, Nandakumar, A, Suzanna, E, Keinan-Boker, L, Silverman, Bg, Ito, H, Hattori, M, Sugiyama, H, Utada, M, Katayama, K, Natsui, S, Matsuda, T, Nishino, Y, Koike, T, Ioka, A, Nakata, K, Kosa, K, Oki, I, Shibata, A, Nimri, O, Ab Manan, A, Bhoo Pathy, N, Ochir, C, Tuvshingerel, S, Al Khater AM, Al-Eid, H, Jung, Kw, Won, Yj, Park, S, Chiang, Cj, Lai, Ms, Suwanrungruang, K, Wiangnon, S, Daoprasert, K, Pongnikorn, D, Geater, Sl, Sriplung, H, Eser, S, Yakut, Ci, Hackl, M, Zielonke, N, Mühlböck, H, Oberaigner, W, Piñeros, M, Zborovskaya, Aa, Henau, K, Van Eycken, L, Dimitrova, N, Valerianova, Z, Šekerija, M, Znaor, A, Zvolský, M, Engholm, G, Storm, H, Aareleid, T, Mägi, M, Malila, N, Seppä, K, Velten, M, Cornet, E, Troussard, X, Bouvier, Am, Faivre, J, Guizard, Av, Bouvier, V, Launoy, G, Arveux, P, Maynadié, M, Mounier, M, Woronoff, As, Daoulas, M, Clavel, J, Le Guyader-Peyrou, S, Monnereau, A, Trétarre, B, Colonna, M, Delacour-Billon, S, Molinié, F, Bara, S, Degré, D, Ganry, O, Lapôtre-Ledoux, B, Grosclaude, P, Lutz, Jm, Belot, A, Estève, J, Forman, D, Sassi, F, Stabenow, R, Eberle, A, Nennecke, A, Kieschke, J, Sirri, E, Kajueter, H, Emrich, K, Zeissig, Sr, Holleczek, B, Eisemann, N, Katalinic, A, Brenner, H, Asquez, Ra, Kumar, V, Ólafsdóttir, Ej, Tryggvadóttir, L, Comber, H, Walsh, Pm, Sundseth, H, Dal Cappello, T, Mazzoleni, G, Giacomin, A, Castaing, M, Sciacca, S, Sutera, A, Corti, M, Gola, G, Ferretti, S, Serraino, D, Zucchetto, A, Lillini, R, Vercelli, M, Busco, S, Pannozzo, F, Vitarelli, S, Ricci, P, Pascucci, V, Autelitano, M, Cirilli, C, Federico, M, Fusco, M, Vitale, Mf, Usala, M, Cusimano, R, Vitale, F, Michiara, M, Sgargi, P, Sacerdote, C, Tumino, R, Mangone, L, Falcini, F, Cremone, L, Budroni, M, Cesaraccio, R, Madeddu, A, Tisano, F, Maspero, S, Tessandori, R, Candela, G, Scuderi, T, Piffer, S, Rosso, S, Zanetti, R, Caldarella, A, Crocetti, E, La Rosa, F, Stracci, F, Contiero, P, Tagliabue, G, Zambon, P, Baili, P, Berrino, F, Gatta, G, Sant, M, Capocaccia, R, De Angelis, R, Verdecchia, A, Liepina, E, Maurina, A, Smailyte, G, Agius, D, Calleja, N, Siesling, S, Laronningen, S, Møller, B, Dyzmann-Sroka, A, Trojanowski, M, Góźdż, S, Mężyk, R, Gądalska-Lampart, M, Radziszewska, Au, Didkowska, J, Wojciechowska, U, Błaszczyk, J, Kępska, K, Bielska-Lasota, M, Forjaz, G, Rego, Ra, Bastos, J, Antunes, L, Bento, Mj, da Costa Miranda AM, Mayer-da-Silva, A, Coza, D, Todescu, Ai, Krasilnikov, A, Valkov, M, Adamcik, J, Safaei Diba, C, Primic Žakelj, M, Žagar, T, Stare, J, Almar, E, Mateos, A, Argüelles, Mv, Quirós, Jr, Bidaurrazaga, J, Larrañaga, N, Díaz García JM, Marcos, Ai, Marcos-Gragera, R, Vilardell Gil ML, Molina, E, Sánchez, Mj, Ramos Montserrat, M, Chirlaque, Md, Navarro, C, Ardanaz, E, Felipe Garcia, S, Peris-Bonet, R, Galceran, J, Khan, S, Lambe, M, Camey, B, Bouchardy, C, Usel, M, Ess, Sm, Hermann, C, Levi, Fg, Maspoli-Conconi, M, Kuehni, Ce, Mitter, Vr, Bordoni, A, Spitale, A, Chiolero, A, Konzelmann, I, Dehler, Si, Laue, Ri, Meechan, D, Poole, J, Greenberg, D, Rashbass, J, Davies, E, Linklater, K, Morris, E, Moran, T, Bannon, F, Gavin, A, Black, Rj, Brewster, Dh, Roche, M, Mcphail, S, Verne, J, Murphy, M, Stiller, C, Huws, Dw, White, C, Lawrence, G, Brook, C, Wilkinson, J, Finan, P, Ahn, Jv, Allemani, C, Bonaventure, A, Carreira, H, Coleman, Mp, Harewood, R, Rachet, B, Sanz, N, Spika, D, Wang, Xs, Stephens, R, Butler, J, Peake, M, Chalker, E, Newman, L, Baker, D, Soeberg, Mj, Scott, C, Stokes, Bc, Venn, A, Farrugia, H, Giles, Gg, Threlfall, T, Currow, D, You, H, Lewis, C, Miles, SA), Epidemiology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, I-20133 Milano, Italy, Bouchardy Magnin, Christine, Usel, Massimo, Allemani, C, Weir, H, Carreira, H, Harewood, R, Spika, D, Wang, X, Bannon, F, Ahn, J, Johnson, C, Bonaventure, A, Marcos Gragera, R, Stiller, C, Silva, G, Chen, W, Ogunbiyi, O, Rachet, B, Soeberg, M, You, H, Matsuda, T, Bielska Lasota, M, Storm, H, Tucker, T, Coleman, M, Vitale, F, University of Zurich, and Coleman, Michel P
- Subjects
Male ,europe 1999-2007 ,Pathology ,Càncer -- Estadístiques ,Survival ,[SDV]Life Sciences [q-bio] ,2700 General Medicine ,Global Health ,Settore MED/42 - Igiene Generale E Applicata ,Neoplasms ,80 and over ,Global health ,Registries ,Stomach cancer ,Child ,cancer survival ,Breast-cancer ,ComputingMilieux_MISCELLANEOUS ,cancer registry ,worldwide ,Cervical cancer ,Aged, 80 and over ,education.field_of_study ,childhood-cancer ,Medicine (all) ,1. No poverty ,General Medicine ,population-based registries ,surveillance ,Middle Aged ,3. Good health ,ovarian-cancer ,Child, Preschool ,population-based registrie ,Female ,net survival ,Neoplasms/mortality ,rectal-cancer ,nordic countries ,data quality ,care ,stage ,Adult ,medicine.medical_specialty ,Adolescent ,Population ,Socio-culturale ,610 Medicine & health ,Age Distribution ,Aged ,Humans ,Infant ,Infant, Newborn ,Sex Distribution ,Survival Analysis ,Young Adult ,Article ,Breast cancer ,SDG 3 - Good Health and Well-being ,cancer registries ,medicine ,Preschool ,education ,Supervivència ,Survival analysis ,ddc:613 ,Cancer -- Statistics ,business.industry ,Cancer ,10060 Epidemiology, Biostatistics and Prevention Institute (EBPI) ,Newborn ,medicine.disease ,Cancer registry ,business ,Demography - Abstract
Worldwide data for cancer survival are scarce. We aimed to initiate worldwide surveillance of cancer survival by central analysis of population-based registry data, as a metric of the eff ectiveness of health systems, and to inform global policy on cancer control. Methods Individual tumour records were submitted by 279 population-based cancer registries in 67 countries for 25·7 million adults (age 15–99 years) and 75 000 children (age 0–14 years) diagnosed with cancer during 1995–2009 and followed up to Dec 31, 2009, or later. We looked at cancers of the stomach, colon, rectum, liver, lung, breast (women), cervix, ovary, and prostate in adults, and adult and childhood leukaemia. Standardised quality control procedures were applied; errors were corrected by the registry concerned. We estimated 5-year net survival, adjusted for background mortality in every country or region by age (single year), sex, and calendar year, and by race or ethnic origin in some countries. Estimates were age-standardised with the International Cancer Survival Standard weights. Findings 5-year survival from colon, rectal, and breast cancers has increased steadily in most developed countries. For patients diagnosed during 2005–09, survival for colon and rectal cancer reached 60% or more in 22 countries around the world; for breast cancer, 5-year survival rose to 85% or higher in 17 countries worldwide. Liver and lung cancer remain lethal in all nations: for both cancers, 5-year survival is below 20% everywhere in Europe, in the range 15–19% in North America, and as low as 7–9% in Mongolia and Thailand. Striking rises in 5-year survival from prostate cancer have occurred in many countries: survival rose by 10–20% between 1995–99 and 2005–09 in 22 countries in South America, Asia, and Europe, but survival still varies widely around the world, from less than 60% in Bulgaria and Thailand to 95% or more in Brazil, Puerto Rico, and the USA. For cervical cancer, national estimates of 5-year survival range from less than 50% to more than 70%; regional variations are much wider, and improvements between 1995–99 and 2005–09 have generally been slight. For women diagnosed with ovarian cancer in 2005–09, 5-year survival was 40% or higher only in Ecuador, the USA, and 17 countries in Asia and Europe. 5-year survival for stomach cancer in 2005–09 was high (54–58%) in Japan and South Korea, compared with less than 40% in other countries. By contrast, 5-year survival from adult leukaemia in Japan and South Korea (18–23%) is lower than in most other countries. 5-year survival from childhood acute lymphoblastic leukaemia is less than 60% in several countries, but as high as 90% in Canada and four European countries, which suggests major defi ciencies in the management of a largely curable disease. Interpretation International comparison of survival trends reveals very wide diff erences that are likely to be attributable to diff erences in access to early diagnosis and optimum treatment. Continuous worldwide surveillance of cancer survival should become an indispensable source of information for cancer patients and researchers and a stimulus for politicians to improve health policy and health-care systems This work was funded by the Canadian Partnership Against Cancer, Cancer Focus Northern Ireland, Cancer Institute New South Wales, Cancer Research UK (C1336/A16148), US Centers for Disease Control and Prevention (CDC; 12FED03123, ACO12036), Swiss Re, Swiss Cancer Research foundation, Swiss Cancer League, and the University of Kentucky (3049024672-12-568)
- Published
- 2014
12. Global surveillance of cancer survival 1995-2009: Analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)
- Author
-
Allemani, C, Weir, HK, Carreira, H, Harewood, R, Spika, D, Wang, XS, Bannon, F, Ahn, JV, Johnson, CJ, Bonaventure, A, Marcos-Gragera, R, Stiller, C, Azevedo E Silva, G, Chen, WQ, Ogunbiyi, OJ, Rachet, B, Soeberg, MJ, You, H, Matsuda, T, Bielska-Lasota, M, Storm, H, Tucker, TC, Coleman, MP, Bouzbid, S, Hamdi-Chérif, M, Zaidi, Z, Bah, E, Swaminathan, R, Nortje, SH, Stefan, CD, El Mistiri, MM, Bayo, S, Malle, B, Manraj, SS, Sewpaul-Sungkur, R, Fabowale, A, Bradshaw, D, Somdyala, NIM, Abdel-Rahman, M, Jaidane, L, Mokni, M, Kumcher, I, Moreno, F, González, MS, Laura, E, Pugh, FV, Torrent, ME, Carballo Quintero, B, Fita, R, Garcilazo, D, Giacciani, PL, Diumenjo, MC, Laspada, WD, Green, MA, Lanza, MF, Ibañez, SG, Lima, CA, Lobo, E, Daniel, C, Scandiuzzi, C, De Souza, PCF, Del Pino, K, Laporte, C, Curado, MP, de Oliveira, JC, Veneziano, CLA, Veneziano, DB, Alexandre, TS, Verdugo, AS, Koifman, S, Galaz, JC, Moya, JA, Herrmann, DA, Jofre, AM, Uribe, CJ, Bravo, LE, Lopez Guarnizo, G, Jurado, DM, Yepes, MC, Galán, YH, Torres, P, Martínez-Reyes, F, Jaramillo, L, Quinto, R, Cueva, P, Yépez, J, Torres-Cintrón, CR, Tortolero-Luna, G, Alonso, R, Barrios, E, Russell, C, Shack, L, Coldman, AJ, Woods, RR, Noonan, G, Turner, D, Kumar, E, Zhang, B, McCrate, FR, and Ryan, S
- Subjects
Adult ,Aged, 80 and over ,Male ,Adolescent ,Infant, Newborn ,Infant ,Middle Aged ,Global Health ,Survival Analysis ,Young Adult ,Age Distribution ,General & Internal Medicine ,Neoplasms ,Child, Preschool ,Humans ,Female ,Registries ,Sex Distribution ,Child ,Aged - Abstract
© 2015 Allemani et al. Open Access article distributed under the terms of CC BY. Background Worldwide data for cancer survival are scarce. We aimed to initiate worldwide surveillance of cancer survival by central analysis of population-based registry data, as a metric of the effectiveness of health systems, and to inform global policy on cancer control. Methods Individual tumour records were submitted by 279 population-based cancer registries in 67 countries for 25·7 million adults (age 15-99 years) and 75 000 children (age 0-14 years) diagnosed with cancer during 1995-2009 and followed up to Dec 31, 2009, or later. We looked at cancers of the stomach, colon, rectum, liver, lung, breast (women), cervix, ovary, and prostate in adults, and adult and childhood leukaemia. Standardised quality control procedures were applied; errors were corrected by the registry concerned. We estimated 5-year net survival, adjusted for background mortality in every country or region by age (single year), sex, and calendar year, and by race or ethnic origin in some countries. Estimates were age-standardised with the International Cancer Survival Standard weights. Findings 5-year survival from colon, rectal, and breast cancers has increased steadily in most developed countries. For patients diagnosed during 2005-09, survival for colon and rectal cancer reached 60% or more in 22 countries around the world; for breast cancer, 5-year survival rose to 85% or higher in 17 countries worldwide. Liver and lung cancer remain lethal in all nations: for both cancers, 5-year survival is below 20% everywhere in Europe, in the range 15-19% in North America, and as low as 7-9% in Mongolia and Thailand. Striking rises in 5-year survival from prostate cancer have occurred in many countries: survival rose by 10-20% between 1995-99 and 2005-09 in 22 countries in South America, Asia, and Europe, but survival still varies widely around the world, from less than 60% in Bulgaria and Thailand to 95% or more in Brazil, Puerto Rico, and the USA. For cervical cancer, national estimates of 5-year survival range from less than 50% to more than 70%; regional variations are much wider, and improvements between 1995-99 and 2005-09 have generally been slight. For women diagnosed with ovarian cancer in 2005-09, 5-year survival was 40% or higher only in Ecuador, the USA, and 17 countries in Asia and Europe. 5-year survival for stomach cancer in 2005-09 was high (54-58%) in Japan and South Korea, compared with less than 40% in other countries. By contrast, 5-year survival from adult leukaemia in Japan and South Korea (18-23%) is lower than in most other countries. 5-year survival from childhood acute lymphoblastic leukaemia is less than 60% in several countries, but as high as 90% in Canada and four European countries, which suggests major deficiencies in the management of a largely curable disease. Interpretation International comparison of survival trends reveals very wide differences that are likely to be attributable to differences in access to early diagnosis and optimum treatment. Continuous worldwide surveillance of cancer survival should become an indispensable source of information for cancer patients and researchers and a stimulus for politicians to improve health policy and health-care systems. Funding Canadian Partnership Against Cancer (Toronto, Canada), Cancer Focus Northern Ireland (Belfast, UK), Cancer Institute New South Wales (Sydney, Australia), Cancer Research UK (London, UK), Centers for Disease Control and Prevention (Atlanta, GA, USA), Swiss Re (London, UK), Swiss Cancer Research foundation (Bern, Switzerland), Swiss Cancer League (Bern, Switzerland), and University of Kentucky (Lexington, KY, USA).
- Published
- 2015
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.